NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
Medical University of Vienna
Boston Medical Center
National Cancer Institute (NCI)